PeptideDB

SJ-1008030 2863634-96-0

SJ-1008030 2863634-96-0

CAS No.: 2863634-96-0

SJ1008030 (compound 8) is a JAK2 PROTAC that selectively degrades JAK2. The IC50 of SJ1008030 for inhibiting the prolife
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

SJ1008030 (compound 8) is a JAK2 PROTAC that selectively degrades JAK2. The IC50 of SJ1008030 for inhibiting the proliferation of MHH-CALL-4 cell line is 5.4 nM. SJ1008030 can be used for the study of lymphocytes.

Physicochemical Properties


Molecular Formula C42H43N13O7S
CAS # 2863634-96-0
Related CAS # SJ1008030 TFA;SJ1008030 formic
Appearance Typically exists as solid at room temperature
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro Compound 8 (SJ1008030) (72 hours) exhibits activity in the MHH-CALL-4 CRLF2r cell line, with an IC50 of 5.4 nM[1]. JAK-STAT signaling nutrients of JAK, GSPT1, and IKZF1 in a dosed manner is suggested by the dose-dependent degradation of JAK2 and GSPT1 proteins in xenografted bone marrow cells SJBALL021415 by SJ1008030 (0-4.3 μM; 72 hours) in MHH-CALL-4 cells and SJ1008030 (0-10 μM; 24 hours)[1].
Cell Assay Cytotoxicity assay[1]
Cell Types: CRLF2r cell lines MHH–CALL-4, KOPN49, MHH–CALL-2, KOP N75, NALM-6 and 697
Tested Concentrations: 0-3 μM
Incubation Duration: 72
Experimental Results: In MHH–CALL The best activity was shown in -4 cells with an EC50 value of 5.4 nM.

Western Blot Analysis[1]
Cell Types: MHH–CALL-4 Cells
Tested Concentrations: 1 nM, 10 nM, 100 nM, 1 μM, and 4.3 μM
Incubation Duration: 72 hrs (hours)
Experimental Results: Significant JAK2-dependent degradation in MHH–CALL-4 cells sex, while the effect on JAK1, JAK3 and GSPT1 is weak.

Western Blot Analysis [1]
Cell Types: Xenograft SJBALL021415 Bone Marrow Cell
Tested Concentrations: 1, 10, 100, 1000 and 1000 nM
Incubation Duration: 24 hrs (hours)
Experimental Results: JAK2 was nearly completely degraded in a dose-dependent manner, with no effect on GSPT1.
References

[1]. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021 Dec 9;138(23):2313-2326.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)